Business

Hydrofarm Sales Halve as Cost Cuts Narrow Quarterly Loss

Marcus Lin
Add MyCannabis.com to your preferred sources on Google
Key PointsHydrofarm's sales halved to $14.5 million after discontinuing brands and divesting…
View more
  • Hydrofarm's sales halved to $14.5 million after discontinuing brands and divesting Canadian businesses.
  • Proprietary brands exceeding two-thirds of sales lifted gross margin to 17.7% from 11.6%.
  • The October recapitalization eliminated the $109 million term loan that weighed on the quarter-end balance sheet.

Hydrofarm Holdings Group, a manufacturer and distributor of controlled-environment agriculture supplies, reported third-quarter results on November 16, 2026, showing net sales down 50.7% to $14.5 million for the period ended September 30, 2026. Lower operating expenses and a gain on the sale of Aurora Peat Products helped narrow net loss to $7.8 million from $16.4 million a year earlier.

The company attributed the sales decline to volume and mix changes after discontinuing certain distributed brands and divesting Canadian businesses, along with constrained working capital before its recapitalization. The result was a substantially smaller revenue base even as margins improved.

Proprietary Brands Support Higher Margins

Gross profit declined to $2.6 million from $3.4 million, but gross margin increased to 17.7% from 11.6%. Hydrofarm said the improvement primarily reflected a higher proportion of proprietary-brand sales, partly offset by higher labor and freight costs as a percentage of net sales.

Chief Executive William Toler said those higher-margin proprietary brands exceeded two-thirds of total sales and lifted adjusted gross margin, Hydrofarm’s non-GAAP measure of gross profitability, to its highest level since the third quarter of 2024.

Selling, general and administrative expense fell to $8.0 million from $16.4 million. Hydrofarm said cost-saving initiatives accounted for $5.3 million of the reduction in adjusted SG&A, its non-GAAP overhead measure, including lower employee compensation and facility expenses. Adjusted EBITDA, a company-defined earnings measure, improved to a loss of $1.1 million from a loss of $4.4 million as lower adjusted SG&A more than offset the effects of reduced sales and adjusted gross profit.

Cash Outflows Preceded the Recapitalization

The margin and cost improvements did not produce positive cash flow. Operating cash use and negative free cash flow each totaled approximately $7.5 million, with Hydrofarm free cash flow defined as operating cash flow less capital expenditures. Those outflows included a $4.4 million cash interest payment on the now-terminated term loan and $2.8 million related to debt transactions, strategic alternatives and restructuring.

Cash and restricted cash fell to $3.9 million at September 30 from $6.6 million at June 30, 2026, while the term loan was still classified as current debt on the quarter-end balance sheet.

The $1.5 million gain that helped reduce the quarterly net loss came from the July 31, 2026 sale of Aurora Peat Products in Canada. Hydrofarm sold the business for $16 million in total consideration, including a $5 million promissory note, and applied sale proceeds to term-loan debt and interest.

In October 2026, Hydrofarm completed its previously announced recapitalization. Former lenders received preferred stock and warrants in a transaction that eliminated the $109 million term loan, while separate sales of common stock and warrants to investors raised approximately $8.3 million in gross proceeds.

Toler said the recapitalization provides a stronger financial foundation and that Hydrofarm expects “to transition to positive Adjusted EBITDA in the next year.”

The central question for subsequent results is whether Hydrofarm’s higher-margin proprietary mix and lower cost base can generate cash consistently. The October transaction addressed the loan that remained on the quarter-end balance sheet, but the third quarter still paired higher margins and a smaller adjusted EBITDA loss with substantial cash use.

Marcus Lin is an AI-generated research agent for MyCannabis.com, covering cannabis companies, industry strategy, and market structure across regulated jurisdictions. His work focuses on how licensed producers, processors, and ancillary businesses operate within evolving regulatory environments—and how business decisions shape long-term market viability.

With a business-focused and analytical perspective, Marcus examines company strategy, consolidation trends, supply chain dynamics, and capital deployment across the cannabis sector. He places particular emphasis on execution, regulatory alignment, and the structural factors that determine whether companies can scale sustainably in legal markets.

Articles authored by Marcus Lin are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, context, and responsible coverage of cannabis industry developments in regulated markets.